Carbon-11-methionine positron emission tomography imaging of chordoma

Skeletal Radiol. 2004 Sep;33(9):524-30. doi: 10.1007/s00256-004-0815-5. Epub 2004 Jul 28.

Abstract

Objective: Chordoma is a rare malignant bone tumor that arises from notochord remnants. This is the first trial to investigate the utility of (11)C-methionine (MET) positron emission tomography (PET) in the imaging of chordoma before and after carbon-ion radiotherapy (CIRT).

Design and patients: Fifteen patients with chordoma were investigated with MET-PET before and after CIRT and the findings analyzed visually and quantitatively. Tumor MET uptake was evaluated by tumor-to-nontumor ratio (T/N ratio).

Results: In 12 (80%) patients chordoma was clearly visible in the baseline MET-PET study with a mean T/N ratio of 3.3+/-1.7. The MET uptake decreased significantly to 2.3+/-1.4 after CIRT ( P<0.05). A significant reduction in tumor MET uptake of 24% was observed after CIRT. Fourteen (93%) patients showed no local recurrence after CIRT with a median follow-up time of 20 months.

Conclusion: This study has demonstrated that MET-PET is feasible for imaging of chordoma. MET-PET could provide important tumor metabolic information for the therapeutic monitoring of chordoma after CIRT.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carbon Radioisotopes / therapeutic use
  • Chordoma / diagnostic imaging*
  • Chordoma / radiotherapy
  • Dose Fractionation, Radiation
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography*
  • Sacrum / diagnostic imaging*
  • Sacrum / radiation effects
  • Spinal Neoplasms / diagnostic imaging*
  • Spinal Neoplasms / radiotherapy

Substances

  • Carbon Radioisotopes